DAIICHI SANKYO EUROPE GmbH
Basic information
- Head office
- Zielstattstr. 48, 81379 Munich, Germany
- Chief executive
- Employees (non-consolidated)
- Employees (consolidated)
- Start date
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Daiichi Sankyo Nordics ApS |
Network
History
Our roots in Europe can be traced back to Luitpold-Werk, a pharmaceutical company founded on 22 January 1910 in Munich, Germany.![]()
The company established its first factory on Munich’s Zielstattstrasse in 1928, with over 100 employees, producing primarily digestive enzymes shipped to about 50 countries.![]()
By 1942, the number of employees had risen to about 300, despite difficulties in obtaining raw materials and limited export options.![]()
In 1943, Munich was bombed, destroying the facilities on Zielstattstrasse. Business activities continued with departments moving to temporary offices and laboratories across the city, leading to the decision to build new production facilities in Pfaffenhofen.![]()
After World War II, business activities resumed within months. In the 1950s and 1960s, new offices in Munich and production facilities in Pfaffenhofen were established.![]()
From 1962, Luitpold-Werk increased its international presence by establishing affiliates in Brazil, Spain, Switzerland, and Italy, and built a new production site in Altkirch, France.![]()
Between 1981 and 1986, subsidiaries were established in the United States, Portugal, and the United Kingdom, expanding Luitpold’s international presence.![]()
Sankyo established two international subsidiaries in New York and Düsseldorf, and Luitpold founded an affiliate in Austria.![]()
Sankyo launched olmesartan (Olmetec®/Benicar®) and acquired Paris-based Laboratories Fornet to expand in Europe.![]()
Sankyo and Daiichi established a joint holding company in Japan named Daiichi Sankyo Company, Limited, followed by the European merger in 2006.![]()
Daiichi Sankyo Europe was founded as the new European headquarters in Munich, integrating business activities in the UK and Germany.![]()
Further investments were made in the German production site in Pfaffenhofen, with new facilities opened.![]()
U3 Pharma was acquired to strengthen oncology pipeline, and rights for Evista® (raloxifene) were acquired from Eli Lilly.![]()
New affiliates opened in Ireland and Turkey; sales force capacity increased by taking over representatives from Merck Serono, growing European employees to nearly 2,500.![]()
Following the earthquake and tsunami in Japan, support was provided to colleagues, including taking over drug production in Pfaffenhofen, and launching 'Daiichi Sankyo Children Aid' for affected children.![]()
Presented Phase III results of the Hokusai-VTE study for edoxaban at ESC congress, and announced results from ENGAGE AF-TIMI 48 study.![]()
Daiichi Sankyo acquired Ambit Biosciences; a new Pharmaceutical Development building was inaugurated at Pfaffenhofen, providing facilities for 100 employees.![]()
Launch of edoxaban, a non-vitamin K antagonist oral anticoagulant (NOAC) and direct factor Xa inhibitor![]()
A licensing agreement was concluded with Esperion for marketing oral bempedoic acid and its fixed-dose combination.![]()
European Commission approval and first launch of bempedoic acid in Europe. Bempedoic acid and its fixed-dose combination with ezetimibe is approved for use in adults with primary hypercholesterolemia or mixed dyslipidemia in Europe![]()
News
There is no news.